The Paxman hair loss prevention system is successfully used around the world on a wide range of cancer types with the most commonly used chemotherapy drug regimes.
Hair loss is the most feared side effect of cancer chemotherapy treatment.
Cooling the scalp during selected chemotherapy regimes has shown to reduce or prevent otherwise inevitable total hair loss.
Hair loss prevention is determined by the degree of control in maintaining the scalp at a constant temperature pre, during and post infusion of the chemotherapy drugs.
Overview of the system
Consideration and care has gone into the design of the system in order to meet the needs of both the patient and nursing staff. It is simple to operate with easy to read touch screen displays. The compact nature and manoeuvrability of the system ensures an efficient use of space.
The system comprises of a small compact mobile refrigeration system connected to lightweight silicone caps.
The patient’s scalp is lowered in temperature to approximately 18°C by circulating a special coolant throughout the cap at -4°C.
The scalp cooler is produced in two models, Orbis I for one patient use and the Orbis II for treating two patients simultaneously.
- High level of patient tolerance and acceptability
- The risk of hair loss is greatly reduced and patients’ self confidence is therefore improved
- Self image is preserved which leads to positive attitudes towards treatment and cure
- Social life and activities need not be inhibited
- Proven success rates
Paxman Scalp Cooling Systems have been shown to be very effective in preventing hair loss following a number of different chemotherapy regimes including Epirubicin, FEC, FAC, Docetaxel and Paclitaxel.
Cancer chemotherapy affects rapidly dividing cells and at any given time, 90% of human hair follicles are in the actively dividing phase. Hair loss frequently occurs due to partial or total atrophy of the hair root bulb, causing constriction of the hair shaft, which then breaks off easily.
Scalp cooling works by inducing vaso-constriction of blood vessels in the scalp, thereby leading to reduced blood flow to the hair follicles in the period of peak plasma concentration of the relevant chemotherapy agent. It is also postulated that reduced biochemical activity due to cooling makes hair follicles less vulnerable to the damage of chemotherapy agents.
Gregory et al² found that alopecia prevention occurred when scalp temperature was reduced below 22°C and Bulow et al³ demonstrated that a subcutaneous temperature below 22°C corresponds to an epicutaneous temperature of 19°C. Results from these tests indicate that the equipment used in the study reduced scalp temperatures to an optimum constant level for alopecia prevention.
The degree of success is determined by how well the scalp temperature is lowered and maintained throughout the treatment period. To achieve this Paxman has designed a special lightweight silicone cap which helps to achieve this. The company has carried out scientific tests to prove the effectiveness of the scalp cooling equipment, the results of which are shown on the graph below.
Our Clinical Efficacy brochure provides an overall summary of effectiveness and tolerance of the Paxman Scalp Cooling System.
Independent observational studies have demonstrated the effectiveness of the Paxman Scalp Cooling System in the prevention of chemotherapy induced hair loss with widely used chemotherapy dosages and regimens.
High levels of comfort and patient acceptability were reported in all trials, with low numbers of patients discontinuing scalp cooling, even when post-infusion cooling extended for 2.5 hours.
Our Clinical Efficacy brochure which details the results of 5 different studies carried out using the Paxman Hair Loss Prevention System, is available to download in full below.
If you require any further information, please contact Access Devices on:
Recommended Cooling Times
It is recommended that patient’s hair is dampened with water, and hair conditioner (ph neutral) is applied to improve scalp contact and reduce the insulation effect of hair.
Where liver function and metabolism of the cytotoxic agent is impaired, scalp cooling may be less effective.
Results with Afro-Caribbean hair are less successful and it is advisable to increase cooling times by ½ to 1 hour.